Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
02 mars 2023 09h15 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA...
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
01 mars 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based...
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
28 févr. 2023 16h05 HE
|
Myriad Genetics, Inc.
Highlights: Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek® Early Gender...
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
22 févr. 2023 07h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth-quarter earnings conference call on...
Myriad Genetics to Participate in Upcoming Healthcare Conferences
09 févr. 2023 07h15 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced management will participate at the...
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
07 févr. 2023 07h15 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted impactful clinical studies from 2022 that...
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
05 janv. 2023 07h05 HE
|
Myriad Genetics, Inc.
Myriad Genetics continues to advance non-invasive prenatal screening with Prequel® and the forthcoming FirstGene™ test using AMPLIFY™ technology SALT LAKE CITY, Jan. 05, 2023 (GLOBE NEWSWIRE) --...
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and chief...
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
19 déc. 2022 16h05 HE
|
Myriad Genetics, Inc.
New leaders to elevate product portfolio, customer-centric commercial capabilities, and sales and marketing execution SALT LAKE CITY, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc.,...
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
08 déc. 2022 19h15 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study...